An Irvine drug maker, Spectrum Pharmaceuticals Inc., has said that it got regulatory approval for an expanded use of a cancer drug.
Spectrum said that the FDA approved Zevalin as an early treatment for a blood cancer, in patients with non-Hodgkin's lymphoma. The drug was used previously on patients whose tumors did not respond to other treatments.
Spectrum Pharmaceuticals and Cell Therapeutics have entered into an agreement to form a 50:50 owned joint venture, RIT Oncology, to commercialize and develop Zevalin in the United States.
- Samsung signs deal with Amazon.in to sell Galaxy K Zoom handset in India
- GE unveils smart LED light bulb – ‘Link’
- Report: iPhone 6 likely to be launched one month earlier than expected
- Huawei officially unveils its new high-end Ascend P7 smartphone
- Samsung launches its ‘Galaxy K zoom’ camera specialized-smartphone